Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Ipsen Biopharmaceuticals, Inc.

Community Practice Connections™: Navigating Treatment Sequencing in Pancreatic Cancer: Experts Paving the Road Toward Patient-Centric Care

Release Date: August 30, 2019
Expiration Date: August 30, 2020
Media: Internet - based

Activity Overview

Pancreatic adenocarcinoma remains among the most challenging malignancies to treat, but with ongoing clinical research comes the continual potential for improvements in patient care and outcomes. In this online activity, Navigating Treatment Sequencing in Pancreatic Cancer: Experts Paving the Road Towards Patient-Centric Care, the latest cutting-edge data will be presented within a framework of patient cases. The experts in pancreatic cancer management will discuss evidence-based, guideline-recommended therapies and potential drug sequencing; the differential clinical profiles of the available treatments, including adverse event as well as pharmacodynamic and pharmacokinetic profiles; and the latest clinical trial developments in the evolving treatment landscape for pancreatic cancer. During this activity, interactive questions interspersed throughout case presentations will give you the opportunity to identify and reflect on the optimal management of pancreatic cancer and how to integrate emerging options into the plan of care for your patients.

Benefits of Participating

  • Learn about the most recent clinical advances for patients with pancreatic cancer.
  • Hear expert discussion of emerging data to guide treatment decision making for patients with pancreatic cancer.
  • Contextualize emerging and investigational therapies into the treatment plan for patients with pancreatic cancer.
  • Gain perspective on how guideline-based care and emerging treatment options can be practically applied to real-world settings in which patients with pancreatic cancer are managed.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Ipsen Biopharmaceuticals, Inc.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Videos" will be available for your reference.
  • In order to receive a CME Certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists, gastroenterologists, gastrointestinal oncologists, and surgical oncologists who treat patients with pancreatic cancer. Other healthcare professionals who have an interest in the treatment of pancreatic cancer, such as endocrinologists, nurses, physician assistants, fellows, and residents, are also invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Outline the scientific rationale for the use of current pancreatic cancer agents/regimens.
  • Summarize recent best practices for individualized, patient-centric approaches to care, including approaches for treatment sequencing in pancreatic cancer.
  • Evaluate the latest clinical trial data of approved and investigational agents in the context of evolving treatment paradigms in the field of pancreatic cancer management.
  • Discuss mitigation and management of treatment-related toxicities across multiple lines of therapy in patients with pancreatic cancer.

Faculty, Staff, and Planners’ Disclosures

Faculty

Eileen O’Reilly
Eileen O’Reilly, MD
Associate Director, Clinical Research
David M. Rubenstein Center for Pancreatic Cancer Research
Attending Physician and Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College
New York, NY

Disclosures: Grant/Research Support: Acta Biologica, Agios, Array, AstraZeneca, Bayer, BeiGene, BMS, Casi, Celgene, Exelixis, Genentech, Halozyme, Incyte, Lilly, MabVax, Novartis, OncoQuest, Polaris, Puma, QED, Roche; Consultant: 3DMedcare, Agios, AlignMed, Amgen, Antengene, Aptus, Aslan, Astellas, AstraZeneca, Bayer, BeiGene, Bioline, BMS, Boston Scientific, Bridgebio, CARsgen, Celgene, Casi, Cipla, CytomX, Daiichi, Debiopharm, Delcath, Eisai, Exelixis, Genoscience, Halozyme, Hengrui, Incyte, Inovio, Ipsen, Jazz, Janssen, Kyowa Kirin, LAM, Lilly, Loxo, Merck, Mina, Novella, Onxeo, PCI Biotech, Pfizer, Pieris, QED, Redhill, Sanofi, Servier, Silenseed, Sillajen, Sobi, Targovax, Tekmira, TwoXAR, Vicus, Yakult, Yiviva.

Andrew H. Ko
Andrew H. Ko, MD
Professor of Clinical Medicine
Interim Division Chief, Oncology
Division of Hematology/Oncology
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, CA

Disclosures: Grant Research Support: Research funding (paid to my institution)or clinical trial support: Roche/Genentech, Celgene, Merrimack, Halozyme, AbGenomics, Apexigen; Consultant: Gritstone, Gilead; Other: Data and Safety Monitoring Committee: Erytech Pharma.

Philip Philip
Philip Philip, MD, PhD
Professor of Medicine
Wayne State University School of Medicine
Clinical Professor of Oncology
Barbara Ann Karmanos Cancer Institute
Detroit, MI

Disclosures: Grant Research Support: AAA, Astellas, Boston Biomedical, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Eisai, Gilead, Halozyme, lncyte, Lilly, Merck, Novocure, QED, Taiho; Biolinx, Tyme, Bayer, Forty Seven, QED; Consultant: AbbVie, Celgene, Lilly, Merck, Rafael; Speakers Bureau: Bristol-Myers Squibb, Celgene, Ipsen, Merck; Other: Advisory Committee: AbbVie, Caris, Celgene, Eisai, Halozyme, Ipsen, Lexicon Pharmaceuticals, Lilly, Merck, Novartis, Rafael, Taiho, Biolinx, Forty Seven; Data and Safety Monitoring Board/ Committee: Aslan, Blueprint, Erytech, Lexicon.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or any of the companies that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
1234567
891011121314
15161718192021
22232425262728
293031
Filter By